Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 496
- Registration Number
- NCT02947685
- Locations
- 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Hamdy A. Azim
- Target Recruit Count
- 160
- Registration Number
- NCT02917005
- Locations
- 🇿🇦
Wits Oncology center, Johannesburg, South Africa
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 388
- Registration Number
- NCT02894398
- Locations
- 🇩🇪
Research Site, Wilhelmshaven, Germany
Palbociclib With Everolimus + Exemestane In BC
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT02871791
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Taizhou EOC Pharma Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT02833155
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT02820961
- Locations
- 🇺🇸
Sarah Cannon Research Institute HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT02765373
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT02732119
- Locations
- 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Midwestern Regional Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02689921
- Locations
- 🇺🇸
Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion, Illinois, United States
🇺🇸Southeastern Regional Medical Center, Newnan, Georgia, United States
Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 221
- Registration Number
- NCT02676986
- Locations
- 🇺🇸
MD Anderson Cancer Centre, Houston, Texas, United States
🇩🇪Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany
🇩🇪Evangelisches Waldkrankenhaus Spandau, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.